Pioneering Tissue Research in Childhood Arthritis

TRICIA is a UK-wide collaborative network advancing research into juvenile idiopathic arthritis through minimally invasive tissue sampling and cutting-edge analytics.

MAPJAG: Mechanisms of Joint and Gut Inflammation in Children and Young People

A clinical observation study investigating inflammation in childhood arthritis

MAPJAG is a multi-site, non-interventional study investigating the relationship between joint and gut inflammation in children and young people with juvenile idiopathic arthritis (JIA). It is the first study of its kind to use minimally invasive synovial biopsy techniques in paediatrics, combined with gut sampling and advanced tissue analysis.

Study Overview

MAPJAG – Mechanisms of Joint and Gut Inflammation in Children and Young People – is designed to enhance our understanding of the biological links between synovial inflammation in the joints and gastrointestinal involvement in JIA. The study provides an unprecedented opportunity to capture high-quality tissue and gut samples from paediatric patients, which can be matched to clinical outcomes over time.

The MAPJAG study aims to:

  • Investigate whether immune responses in the gut are reflected in joint inflammation, and vice versa

  • Collect matched synovial biopsy and stool/gut mucosal samples from participants at baseline and during disease progression

  • Use spatial and molecular analysis to identify cell types, immune markers, and inflammatory patterns

  • Associate these findings with real-world clinical outcomes, treatment escalation, and disease remission or persistence

What's Involved

Participants in MAPJAG are children and young people under the care of paediatric rheumatology teams who may be undergoing a clinical procedure such as a joint steroid injection. At the same time, they may be invited to:

  • Provide synovial tissue samples via ultrasound-guided biopsy

  • Provide stool samples and/or gut mucosal swabs

  • Complete a brief questionnaire about their symptoms and quality of life

  • Return for follow-up assessments, including blood tests or repeat sampling where clinically appropriate

All participation is voluntary. No experimental treatments are involved, and each site follows a rigorous, ethically approved protocol designed in consultation with families and healthcare professionals. Children and their families are fully supported by experienced clinical teams trained in both medical care and research delivery.

Where It's Happening

MAPJAG is currently live at several TRICIA-affiliated NHS paediatric rheumatology centres, including:

  • Birmingham Women’s and Children’s NHS Foundation Trust – the lead site for the MAPJAG study, providing coordination across the network and leading on biopsy training, ethics, and data integration.

  • Great Ormond Street Hospital for Children NHS Foundation Trust – a key early adopter site actively contributing to participant recruitment and sample collection with a strong translational research infrastructure.

These centres are fully trained in TRICIA’s standardised protocols and play a pivotal role in the delivery and refinement of the study approach.

Additional sites are in various stages of feasibility and training, with the aim of expanding access across the UK.

Analysis and Impact

The MAPJAG study generates high-resolution biological data that can provide a window into how JIA develops and behaves. Samples undergo multi-layered analysis using technologies such as:

  • Histology and immunostaining to examine cell types and tissue architecture

  • Spatial transcriptomics to localise gene expression changes within the joint

  • Metagenomics and microbiome profiling to analyse microbial composition and functional genes in the gut

These data are analysed alongside clinical features such as disease duration, treatment response, and flare frequency. The aim is to identify biomarkers that can inform patient stratification, predict disease trajectory, and ultimately guide targeted treatment strategies for children with JIA.

Get Involved or Learn More

We welcome questions from families, clinicians, researchers, and partner sites. To learn more about MAPJAG or how to support the study:

The MAPJAG study is adopted into the clinical research network (CRN) portfolio.

Study Information:

Study Title: Mechanisms of Joint Inflammation in Children and Young People with Juvenile Idiopathic Arthritis
IRAS Project ID: 292585
REC Reference: 21/EE/0103
Sponsor: University of Birmingham

Funding:

  • Initially established through the Arthritis Therapy Acceleration Programme (A-TAP), funded by the Kennedy Trust for Rheumatology Research. This funding enabled the development of the observational study, laying the groundwork for paediatric synovial biopsy research
  • The study later received further support from Versus Arthritis through the Multiomic Analysis of Paediatric Joint and Gut Inflammation (MAPJAG) and;
  • The UK Research and Innovation (UKRI) Medical Research Council (MRC) through a Partnership Award. This support strengthens the infrastructure for multi-centre synovial tissue research, ensuring the continued integration of synovial biopsies into clinical trials and routine care.
  • This study has been delivered through the National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the research funders, the NIHR, or the Department of Health and Social Care.